Aptagen, LLC
T3 (ID# 8186)
DNA
Ovarian cancer tumor cells
Tissue
PBS with 5 mM MgCl2
37°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
highly specific to tumor cells present in the tumor tissue of high-grade serous ovarian cancer (HGSC) lines
5'-dCsdGsdCsdTsdCsdGsdGsdAsdTsdCsdGsdAsdTsdAsdAsdGsdCsdTsdTsdCsdGsdAsdGsdCsdCsdTsdGsdAsdGsdTsdTsdTsdTsdTsdGsdCsdCsdGsdCsdGsdAsdTsdCsdTsdCsdGsdAsdCsdCsdTsdCsdCsdGsdTsdCsdAsdCsdGsdGsdAsdTsdCsdCsdTsdCsdTsdAsdGsdAsdGsdCsdAsdCsdTsdGs-3'
75
22910.14
679131
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Wang, Hongyu et al. “Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.” BioTechniques vol. 61,5 249-259. 1 Nov. 2016, doi:10.2144/000114473
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.